Analysis Of Small Cell Lung Cancer PFS Affected Factors

[Objective]Retrospective investigation of the clinical features of small cell lung cancer (SCLC), explore the impact of the SCLC progression-free survival time (PFS) and prognostic factors for small cell lung cancer diagnostic and treatment practices or guidelines to provide some of the data.[Methods]Collectting the Third Affiliated Hospital of Kunming Medical University from January2008to8,2011by pathologically confirmed previously untreated patients with small cell lung cancer, through the analysis of the clinical data collected, including the staging of small cell lung cancer, the patient’s gender, age,the general condition of blood biochemical indicators LDH, tumor markers NSE. treatment, analysis the impact SCLC progression-free survival time and prognostic factors.[Results]1、The blood LDH and SCLC progression-free survival (PFS).the difference was statistically significant (t=1.545, P=0.026).2、The blood NSE and SCLC progression-free survival (PFS),the difference was statistically significant (t=2.501, P=0.014).3、Hyponatremia and SCLC progression-free survival (PFS) was no significant difference (t=0.399, P=0.691).4、Differences in gender and SCLC progression-free survival (PFS) was not statistically significant (t=1.622, P=0.108).5、Age and SCLC progression-free survival (PFS) was no significant difference (t=-0.280,P=0.780).6、ECOG score with SCLC progression-free survival (PFS) difference was statistically significant (t=2.450, P=0.016).7、Weight changes and SCLC progression-free survival (PFS),the difference was not statistically significant (t=0.786, P=0.434).8、Smoking index with SCLC progression-free survival (PFS) was no significant difference (t=0.041, P=0.968).9、Staging and SCLC progression-free survival (PFS), the difference was statistically significant (t=3.368, P=0.001). PFS in patients with extensive stage patients with PFS compared with limited-short.10、Treatment and SCLC progression-free survival (PFS), the difference was statistically significant (t=3.368, P=0.001). Patients radiotherapy and chemotherapy compared to chemotherapy alone PFS long.11、Sites of metastases (liver, bone, brain, adrenal, etc.) with SCLC progression-free survival (PFS), the difference was not statistically significant.12、Linear stepwise regression results show that:the staging and treatment of small cell lung cancer is important revevant factors.and can affect the SCLC progression-free survival time (PFS).[Conclusions]1、High serum LDH, elevated serum NSE, high PS score, advanced stage, pure chemotherapy of patients with small cell lung cancer have shorter PFS.2、Decreased serum sodium, sex, weight loss, smoking index, the number and parts with wide focal shift has nothing to do with small cell lung cancer patients with PFS.3、Linear stepwise regression results show that:the staging and treatment of small cell lung cancer is important revevant factors.and can affect the SCLC progression-free survival time (PFS).